NDAINJECTIONINJECTABLE
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESPRIN (triflupromazine hydrochloride) is a first-generation antipsychotic administered by injection, approved in 1958 for psychiatric indications. As a phenothiazine derivative, it blocks dopamine receptors in the central nervous system to manage psychotic symptoms. This legacy product represents an earlier era of antipsychotic therapy before modern atypical agents became standard of care.
LOE Approaching
Product faces imminent loss of exclusivity with minimal commercial investment; supporting team likely scaled for maintenance-only operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VESPRIN presents minimal career growth opportunity given its approaching loss of exclusivity and negligible job pipeline (0 linked roles). Career value lies in legacy product management expertise, operational discipline, and portfolio rationalization experience rather than innovation or market expansion.
Brand ManagerField Sales Representative
Worked on VESPRIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.